Related Experiment Videos
Tissue polypeptide specific antigen (TPS) in breast cancer--an initial evaluation
D M O'Hanlon1, M J Kerin, C O'Boyle
1National Breast Cancer Research Institute, University College Hospital, Galway, Ireland.
Summary
Tissue Polypeptide Specific-Antigen (TPS) shows promise as a breast cancer marker. Elevated TPS levels correlate with advanced disease stages and recurrence, aiding in tumor burden assessment.
Area of Science:
- Oncology
- Biomarkers
Background:
- Tissue Polypeptide Specific-Antigen (TPS) is a marker of cell proliferation.
- Evaluating TPS in breast carcinoma and benign breast disease is crucial for understanding its clinical utility.
Purpose of the Study:
- To assess the correlation of TPS levels with breast carcinoma stage, tumor size, and lymph node involvement.
- To evaluate the utility of TPS in identifying and monitoring recurrence and metastatic disease during patient follow-up.
Main Methods:
- TPS was measured pre-operatively in 258 patients (216 with breast carcinoma, 42 with benign breast disease).
- Correlation analysis was performed between TPS levels and disease stage, tumor size, and lymph node status.
- TPS levels were monitored during follow-up to assess recurrence and metastatic disease.
Main Results:
- TPS levels increased with advancing disease stage (Stage I-IV) and increasing tumor size.
- No significant correlation was found between TPS levels and the number of involved lymph nodes.
- Significantly elevated TPS levels were observed in patients with loco-regional recurrence and metastatic disease, with the highest levels in disseminated disease.
- Elevated TPS during follow-up predicted a higher likelihood of disease progression.
Conclusions:
- TPS may serve as a valuable index of tumor burden in breast carcinoma.
- Further large-scale studies are warranted to confirm TPS's role in identifying and managing recurrent breast cancer.